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The term spondyloarthritis (SpA) encompasses a broad clinical spectrum characterized
by chronic inflammatory conditions affecting the sacroiliac joints, the spine but also
peripheral joints and tendons and being additionally associated with the involvement
of organs, such as bowel, eye and skin (1). Musculoskeletal pain is a key symptom
in SpA. However, although low back pain and/or joint pain are characteristic for SpA,
undifferentiated pain at different enthesial sites may also be a concomitant or even the
first clinical presentation in some patients (2). In addition, fatigue is another important
symptom often reported by patients with SpA, which substantially affects the quality of
life (QoL) (3). Fibromyalgia (FM) is the most common diagnosis in patients complaining
of chronic diffuse pain with fatigue and may occur alone or in association with chronic
inflammatory diseases (4). The prevalence of FM ranges from 2 to 8% in the general
population and it can reach up to over 50% in patients with other rheumatic and
musculoskeletal diseases (RMDs) (5–7). FM has been identified as the most disabling
RMD, based on the patients’ perception that their medical condition is not properly
recognized (8). This is also due to the poor knowledge about its pathogenesis, and
therefore the lack of reliable biomarkers reveals a major unmet need requiring to
be addressed in further research studies. Over the last decade, an increasing body
of evidence described the impact of FM in SpA highlighting the pitfalls for correct
classification, appropriate differential diagnosis and assessment of outcome measures
in both conditions. The purpose of this review is to provide an overview of currently
available data with regard to the coexistence and reciprocal features of FM and SpA.
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CRITERIA FOR FM AND SpA: STATE OF THE ART
From Psychogenic Rheumatism to Fibromyalgia Syndrome
The term FM was initially proposed in 1975 (9) to replace the old term fibrositis and was officially
approved by the American College of Rheumatology (ACR) Committee while developing the 1990
classification criteria (10). The evidence that widespread pain was a key symptom complained
of patients and that trigger points were the most powerful discriminator between patients and
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controls, led to the inclusion of these two observations as
classification criteria for FM (10). Compared to the first set
of criteria, that were highly specific but poorly sensitive and
therefore missed a consistent proportion of FM patients, the ACR
1990 criteria ensured a higher sensitivity. However, after 20 years
and many debates on the same matter, it became evident that
the 1990 criteria had similar major pitfalls. The lack of proper
implementation of trigger point assessment in daily practice,
mainly in primary care where most of FM diagnosis occur,
led to symptom-based rather than criteria-based identification
of patients. Furthermore, the lack of other key manifestations
within the FM-related clinical spectrum, such as fatigue and
cognitive symptoms, was a major argument underpinning the
need of a new set of criteria. The Manchester criteria were
published in 1996 and used a widespread pain diagram to
establish the diagnosis, but still did not include other relevant
domains in the clinical spectrum of FM (11). In 2003, the
combination of a Regional Pain Scale (RPS) score, combined with
a fatigue score on a visual analog scale (VAS), was proposed (the
so-called “Survey criteria”) (12, 13) and a few years later, an ACR
committee was convened to build the ACR 2010 preliminary
diagnostic criteria. In these criteria, the widespread pain index
(WPI) and the symptom severity (SS) scale score were included
to encompass the wide clinical picture of FM. Using the 2010
criteria, patients may be diagnosed with FM if they fulfill specific
cut-offs, both for theWPI and the SS concomitantly to symptoms
lasting for ≥3 months and no other condition that could explain
their pain (14). In 2011, a modified version of the 2010 criteria
was proposed that relied on self-reported pain and a simplified
self-reported version of somatic symptoms (15). Finally, criteria
combining the 2010 and the modified 2011 set were released in
2016 (16). In parallel to the release of the 2010 diagnostic criteria,
the French Rheumatic Pain Study Group (Cercled’Etude de la
Douleur en Rhumatologie, CEDR) developed and validated a
patient self-completed questionnaire for the detection of FM in
patients with chronic widespread pain: the Fibromyalgia Rapid
Screening Tool (FiRST) (17). A previous screening tool, to be
employed in epidemiological studies, the London Fibromyalgia
Epidemiology Study Screening Questionnaire (LFESSQ) was
developed in 1999 (18) while the FiRST, owing to its briefness and
good performance, was tailored to be a companion for clinicians
in daily practice. FM should no longer be viewed merely as the
physical manifestation of psychological distress but instead as a
central and peripheral pain hypersensitivity syndrome that could
be secondary, in some cases, to the chronic inflammation. On this
basis, FM should be diagnosed based on positive criteria instead
of by elimination and should be managed in its own right in
patients with other comorbidities, including rheumatic diseases.
The Kaleidoscope of Criteria for
Spondyloarthritis
Several sets of classification criteria have been proposed over
the last decades not only to ensure the correct identification
of patients displaying different clinical features, but also
to acknowledge and incorporate the evolution of imaging
techniques and the compelling need to reduce the diagnostic
delay (19). The human leukocyte antigens (HLA) B27 gene, the
natural function of which is to present intracellular peptides
to cytotoxic T lymphocytes, is strongly associated with SpA
(20). The prevalence of HLA-B27 in the general population
ranges from around 2 to 6% (21, 22), while it reaches 94% in
AS (20). However, in other phenotypes of the SpA spectrum,
HLA-B27 can be detected in lower proportions ranging from
30 to 75% (20). Inflammatory back pain (IBP) is a hallmark
of axial SpA (axSpA) and its features were defined in several
sets of criteria (23–26). The insidious onset of back pain
lasting for at least 3 months, associated with morning stiffness
improving with exercise in an individual aged 40–45 years or
below, represented the basis for subsequent criteria for axSpA
including the Assessment of Spondyloarthritis International
Society (ASAS) 2004 (24), the Berlin 2006 (25) and the ASAS
2009 (26). In parallel, Calin’s definition was also incorporated
in the framework of the 1966 New York criteria for ankylosing
spondylitis (AS) (27) which modified version was released in
1984 (28). The first set of criteria encompassing the entire
clinical spectrum of SpA was developed by Amor in 1990 (29),
followed by the European Spondylarthropathy Study Group
(ESSG) criteria of 1991 (30) and the ASAS (24, 26). With regard
to PsA, the definition of Moll and Wright in 1973, evolved and
culminated in the latest set of criteria which is currently used,
was released in 2006 by the classification of psoriatic arthritis
(CASPAR) study group (31). An open question fuelling the
debate in the scientific community is the one relating to non-
radiographic axial (nr-ax)-SpA (32). The ASAS 2009 criteria
include a milestone in this regard, as the item “sacroiliitis on
imaging” now includes not only definitive radiographic changes
according to modified New York criteria but also acute bone
marrow oedema on magnetic resonance imaging (MRI), highly
suggestive of SpA. In this regard, the ASAS-OMERACT MRI
group defined active sacroiliitis on MRI based on the kind (bone
marrow oedema/osteitis, synovitis of sacroiliac joints, enthesitis
or capsulitis) and extension of lesions (33).
THE PERFORMANCE OF FM CRITERIA IN
PATIENTS WITH CONCOMITANT SpA AND
VICE-VERSA
The complexity of SpA and FM clinical pictures, along with the
different classification criteria available, account for the difficulty
to compare studies exploring FM prevalence in SpA and vice-
versa. A recent systematic literature review and meta-analysis
discussed 10 studies assessing FM prevalence in SpA using the
ACR 1990 and/or 2010 classification as inclusion criteria (7)
but, as summarized in Table 1, the actual number of available
studies is higher. It is interesting to note that the large majority
of studies, many of which were published after the release of
the 2010 ACR criteria, still assessed FM with the 1990 ACR
criteria (6, 34–40, 42, 44, 50), while only four used the 2010 ACR
criteria (41, 47, 49, 52) and only two used both criteria (45, 48).
Four studies explored the FiRST tool either alone (43) or in
comparison to the ACR 1990 (46, 53) or ACR 2010 (51) criteria.
With regard to AS, data resulting from over one thousand
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TABLE 1 | Studies evaluating the prevalence of fibromyalgia in patients with spondyloarthritis.
References Disease N◦ pts SpA criteria FM
(1990 criteria)
FM
(2010 criteria)
FM
(FiRST)
Aloush et al. (34) AS 36 Mod. New York 25% NA NA
Almodóvar et al. (35) AS 462 Mod. New York 4.1% NA NA
Azevedo et al. (36) AS 71 Mod. New York 15% NA NA
Husted et al. (37) PsA 390 CASPAR 27.2% NA NA
Roussou and Ciurtin (38) SpA
PsA
60
20
Calin and Berlin
CASPAR
30% TeP criterion
50% TeP criterion
NA NA
Husted et al. (39) PsA 631 CASPAR 22% NA NA
Demirdal et al. (40) AS 71 Mod. New York 16.9% NA NA
Salaffi et al. (41) AS
axSpA
211
191
Mod. New York
ASAS
NA 12.7%
17.2%
NA
Haliloglu et al. (6) AS 119 New York 12.6% NA NA
Graceffa et al. (42) PsA 74 CASPAR 16% NA NA
Bello et al. (43) SpA 185 ASAS NA NA 20.5%
Wach et al. (44) axSpA
pSpA
81
22
Amor and ASAS
ESSG and ASAS
14.8%
27.3%
NA NA
Brikman et al. (45) PsA 73 CASPAR 8.2% TeP criterion
1.4% both criteria
16.4% NA
Fan et al. (46) AS
nr-axSpA
pSpA
PsA
126
64
52
New York
ASAS
ASAS
CASPAR
6.4%
23.9%
NA
9.6%
NA 22.3%
36.4%
NA
22.9%
Macfarlane et al. (47) SpA 1,041
398
65
Mod. New York
ASAS radiological
ASAS clinical
NA 19.7%
25.2%
9.5
NA
Baraliakos et al. (48) axSpA 200 ASAS 13.5% 24% NA
Di Carlo et al. (49) PsA 144 CASPAR NA 18.8% NA
Fan et al. (50) AS
PsA
pSpA
nr-axSpA
137
59
38
64
Mod. New York
CASPAR
ASAS
ASAS
6.4%
9.6%
5.3%
23.9%
NA NA
Dantu et al. (51) axSpA 25 ASAS NA 60% 36%
Dantu et al. (52) axSpA 51 ASAS NA 47% NA
Moltó et al. (53) axSpA 441
85
ASAS
Any except ASAS
13.2
32.9
NA 38%
41.2%
N◦, number; Pts, patients; FM, fibromyalgia; AS, ankylosing spondilytis; SpA, spondyloarthritis; ax, axial; p, peripheral; PsA, psoriatic arthritis; nr, non-radiographic, TeP, tender points;
NA, not assessed; ASAS, Assessment of Spondyloarthritis International Society; CASPAR, classification of psoriatic arthritis; ESSG, European Spondylarthropathy Study Group; FiRST,
Fibromyalgia Rapid Screening Tool.
patients demonstrate a prevalence of FM ranging between 6.4
and 25% based on the ACR 1990 criteria (6, 34–36, 40, 46, 50).
The only study using the ACR 2010 criteria, enrolling 211 AS
patients, observed a prevalence of 12.7% (41), while the study
using the FiRST tool reported a prevalence of 22.3% of FM in AS
(compared to a prevalence of 6.4% with the ACR 1990 criteria)
(46). In studies assessing FM in overall axSpA according to the
ASAS criteria without prior FM diagnosis, the prevalence was
13.2% with the ACR 1990 criteria (48, 53), between 17.2 and 60%
with the ACR 2010 criteria (41, 51) and 36% with the FiRST tool
(51).
The study considering nr-axSpA as a separate entity reported
a prevalence of FM of 23.9% and 36.4% using the ACR 1990
criteria and the FiRST tool, respectively (46). In peripheral
(pSpA) according to either ESSG or ASAS criteria the prevalence
of FM was assessed only with the ACR 1990 criteria and resulted
between 5.3 and 27.3% (44, 50). All available studies on PsA used
the CASPAR criteria and reported a prevalence of FM ranging
from 1.4 to 37.3% with the ACR 1990 criteria (37, 39, 42, 45, 46)
and from 16.4 to 18.8% with the ACR 2010 criteria (45, 49). The
main observation arising from the above mentioned studies is
that, despite the pitfalls pointed out about the 1990 ACR criteria
(the lack of their adequate implementation in clinical practice),
and most importantly, the availability of a new and more recent
set of criteria, these are still the most commonly employed
for research purposes. It is therefore difficult to translate these
results into clinical practice and, most importantly, to fully
understand similarities and differences not only among the two
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TABLE 2 | Studies evaluating the prevalence of spondyloarthritis in patients with fibromyalgia.
References N◦ pts Criterion for FM
diagnosis
SpA
prevalence
nr-axSpA Fulfilled
criteria
Kas¸kari et al. (54) 41
15
ACR 1990 or 2010
ACR 1990 and 2010
31.7%
46.6%
NA Amor and
ESSG
Baraliakos et al. (48) 100 ACR 1990 and ACR 2010 2% 0 ASAS
Roussou and Georgiou (55) 95 ACR 2010 62%
69%
23%
NA Calin
Berlin ASAS
Ablin et al. (56) 99 ACR 1990 10% 2 ASAS
N◦, number; Pts, patients; FM, fibromyalgia; ACR, American College of Rheumatology; SpA, spondyloarthritis, nr-ax, non-radiographic axial; NA, not assessed; ASAS, Assessment of
Spondyloarthritis International Society; ESSG, European Spondylarthropathy Study Group.
sets of ACR criteria but also with recent tools, such as the
FiRST.
When looking at how many patients with FM would fulfill
SpA criteria, the number of related publications is much lower
and, as a consequence, the results even less clear (Table 2). In
one study conducted in patients diagnosed with FM according
to the ACR 1990 criteria, only 10% fulfilled the ASAS criteria
(56). Of these, 80% fulfilled the ASAS criteria based on MRI
findings diagnostic of sacroiliitis and the remaining 20% fulfilled
the criteria based on the presence of HLA–B27 and SpA features.
The study by Rousseau et al explored how many patients with
FM would fulfill three sets of clinical criteria for SpA according
to the ACR 2010 criteria. Over 60% of FM patients fulfilled either
the Calin or the Berlin criteria, while 23% fulfilled the clinical
arm of the ASAS criteria (55). No data are available regarding the
evidence of radiographic or MRI sacroiliitis. In another cohort of
FM patients diagnosed according to the ACR 2010 criteria, only
2% of them fulfilled the ASAS criteria (48). Interestingly, such
low prevalence could be explained by the prospective nature of
the study in a real-life population of patients with axSpA. When
assessing the subgroup of FM patients with HLA-B27 available,
this proportion raised to 5% but still remained very much below
the 23% observed by Roussou and Georgiou (55). Finally, when
considering the Amor or ESSG criteria, they were fulfilled by
almost half of FM patients (diagnosed with the ACR 1990 and
2010 criteria) (54). Of interest, the prevalence of radiographic
sacroiliitis grade 2 or higher was similar in patients’ subgroups
fulfilling either ACR 1990, ACR 2010 or both set of criteria
and was around 30%. Of those with sacroiliitis grade 1 or 2 at
conventional radiograms, only 4% displayed sacroiliitis at MRI.
These findings open an intriguing scenario for further discussion
which also includes the relevance of imaging in shedding some
light on the actual co-existence, with consequent therapeutic
implications, of FM and SpA. Moreover, it should be kept into
account that fatigue can be detected in up to half SpA patients
(57). This can be due not only to disease activity but notably
also to psychogenic factors, especially depression. Therefore, it
is imperative to rule out whether we are dealing with SpA-
related fatigue, psychogenic fatigue or an actual diagnosis of
FM. Unfortunately, such distinction is not easy, therefore, the
question remains on whether it came first the chicken or the
egg.
IMAGING TO DIFFERENTIATE SpA FROM
FM
The observation that FM patients may fulfill SpA criteria and
the need to differentiate active SpA features from FM for
appropriate therapeutic management, point out the importance
to complement clinical assessment with imaging techniques.
With regard to IBP, radiographic sacroiliitis has long been
a hallmark of the classification of AS, within the axSpA
spectrum (58). However, this may not be present in early
phases of the disease and some patients may never develop such
major structural damage, as discussed above. In this scenario,
and according to the ASAS 2009 criteria, the evaluation of
sacroiliac joints through MRI is therefore crucial. A still open
question is whether the ASAS classification criteria may lead to
overinterpretation and misclassification, which in consequence,
may induce overtreatment of patients with chronic back pain
and FM, who may just show minor MRI changes or a positive
HLA-B27 finding (48). An evenmore challenging scenario is SpA
presenting as polyenthesitis without axial involvement and here
the role of imaging is of utmost importance. Enthesitis, defined
as inflammation of tendon, ligament, and joint capsule insertions
to the bones, is a hallmark of SpA (59). Entheseal regions are
well-innervated, but are completely avascular at attachment sites
and have a low density of blood vessels in the adjacent ligaments
and tendons (60). On this basis, although pain, tenderness
and stiffness are its main clinical manifestations, in most cases
enthesitis occurs without visible signs of clinical inflammation
and without increased acute phase reactants (61). Moreover,
many entheses are not clinically accessible, located deep inside
the human body. Often, clinical examination of enthesitis is
inconclusive and the decision to initiate or adapt therapy is
difficult. Finally, these entheseal SpAmay be extremely difficult to
distinguish from FM. The enthesitis score used in SpA has been
criticized owing to its lack of correlation with objective measures
of enthesitis, such as MRI, and because it overlaps with the FM
tender point score (38, 62). From these anatomical and clinical
considerations, in order to differentiate SpA-related enthesitis
and FM, we require sensitive and advanced imaging techniques.
Radiography only detects changes at a relatively late stage of
disease, such as periosteal bony apposition or bony erosions, and
is inferior to MRI in the evaluation of the disease extent and
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severity (63, 64). Scintigraphy has been widely used in the past;
however, due to its lack of specificity it has been replaced by
MRI and ultrasound (US) (65, 66). Despite providing interesting
preliminary results (67, 68), positron emission tomography
(PET) does seem neither specific nor able to offer the same
excellent spatial resolution as MRI, requiring further research in
this field.
Musculoskeletal US with power Doppler (PDUS) is a valid
and reliable means of evaluating SpA enthesitis (69). On
this basis, PDUS may provide further helpful information for
distinguishing enthesitis and FM. However, it is important
to highlight that age-related changes may occur at normal
entheses, particularly in patients with high body mass index
(BMI), so it is possible that patients with FM may show
some degree of entheseal change. Some studies suggest that
abnormal vascularity at the entheseal level characterize SpA
patients, even if asymptomatic, with respect to healthy controls
(70–72), although the presence of Doppler positivity seems to
have a low sensitivity (36%) (72). The range of enthesophytes,
a chronic entheseal change, in healthy controls overlapped
the ranges of patient with psoriasis and PsA (72). However,
enthesophytes are not specific to enthesitis and may be related
to mechanical forces. In a pilot study comparing PDUS-revealed
entheseal involvement in patients with PsA and patients with FM,
Marchesoni and colleagues concluded that PDUS assessment of
peripheral entheses appears to be able to differentiate patients
with PsA and patients with FM in terms of number and
distribution of involved sites as well as presence of inflammatory
changes (73). However, since the presence of at least 1 lesion at
1 site was quite common in patients with FM (80%), a cut-off
point of ≥3 involved sites has been set, providing the greatest
discriminating power in patients with PsA, who were the only
patients with bony erosions. Inflammatory changes were present
in the majority of PsA patients, and the involvement of plantar
fascia and Achilles tendon was highly specific of PsA. Many
entheseal sites are not accessible for US scans, and, especially
in patients with chronic widespread pain, such as FM, their
assessment requires an excessive amount of scanning time. MRI
methods could overcome the difficulties in the assessment of
deeply located enthesis. On MRI, enthesitis is associated with
diffuse perientheseal soft tissue oedema that is more conspicuous
than inflammation within the insertion, reflecting the greater
vascularity of the peri-entheseal tissues (59). In this context,
adjacent osteitis may be present, due to the consistent vascularity
of the bone marrow. In their small prospective study, Godfrin
and colleagues used technetium 99m angioscintigraphy andMRI
to assess entheses, focusing on sites where the pain was the
most severe or where radionuclide scanning showed increased
uptake, and a good agreement between radionuclide scanning
and MRI was found (74). In particular, radionuclide scanning
and MRI findings establish that isolated entheseal pain could
indicate SpA, while both investigations are normal in patients
with FM. In contrast to conventional MRI, which only covers
one anatomical area in one scan, whole-body MRI (WB-MRI)
allows assessment of all peripheral and axial joints and entheses
from “head-to-toe” in one examination (75). The WB-MRI
technique could ensure better assessment of disease extent and
activity within one examination and therefore improve the
detection of entheseal inflammation (76), unmasking clinically
silent enthesitis (77), while being less obtrusive for patients.
Enthesitis can be detected onWB-MRI with moderate agreement
between WB-MRI and clinical examination, and, interestingly,
patients had more enthesitis at clinical examination than on
WB-MRI, whereas it was the opposite for healthy subjects. This
may be explained by the presence of subclinical enthesitis, which
may be related to other conditions inducing mechanical stress,
such as high BMI or physical overuse (77). Although all the
above progress is promising, WB-MRI technique is still under
development and, before widespread clinical use, robust research
and clarification concerning entheseal abnormalities found also
in healthy subjects are needed (61). Although enthesitis is
considered as the primary pathological process underling SpA,
it is still difficult to differentiate whether patients have poly-
enthesitis, FM or both, because the physical examination may be
similar, and other clinical features, for example the response to
NSAIDs, need to be taken into consideration. Furthermore, as
mentioned above, the poorly understood pathophysiology of FM
and the lack of reliable diagnostic biomarkers further complicate
this matter. At present, imaging with PDUS scanning or selected
MRI scanning of sites with predominant pain, seem to be the
most useful tool to be used in this process. In the future, more
advanced and sophisticated imaging techniques, such as PET in
combination with CT or MRI, or whole-body MRI may be used
for this purpose.
FM IMPACT ON SpA OUTCOME
MEASURES
Given the considerable coexistence of SpA and FM, another
crucial point is the impact of the latter on SpA outcome
measures and therefore the implications of therapeutic tailoring
(78). Patients with AS and FM usually report significantly
worse disease activity, function, global severity scores, and QoL
(47). The AS-QoL score is higher in patients with SpA and
FM (B, C, G) and several studies agree that patients with
SpA and FM display also higher Bath ankylosing spondylitis
disease activity index (BASDAI) scores (6, 34–36, 40, 47) and
poorer function scores, as calculated with the Bath Ankylosing
Spondylitis Functional Index (BASFI) (34–36, 43). In this
regard, objective measures play a major role in discriminating
the inflammatory SpA component of disease activity/damage
assessment andminimize the interference of FM clinical features.
This is supported by the evidence that the ankylosing spondylitis
disease activity score (ASDAS)-C reactive protein (CRP), and
to a lesser extent the ASDAS-erythrocyte sedimentation rate
(ESR), where acute phase reactants are the item with the highest
weight, are better discriminators compared to the BASDAI that
only includes 10mm visual analogic scales to be compiled by
the patient (41, 44). Likewise, the Bath Ankylosing Spondylitis
Radiology Index (BASRI), including AS-specific radiographic
changes, is reduced in patients with comorbid FM and, in this
regard, Almodovar and colleagues suggested a BASDAI/BASRI
ratio equal or over 1.5 to identify patients at high probability
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to have FM associated with SpA (positive likelihood ratio of
3.1) (35). With regard to PsA, the composite psoriatic disease
activity index (CPDAI) and the disease activity index for psoriatic
arthritis (DAPSA) scores are higher in patients with concomitant
FM (45). This also applies to a recently validated patient reported
outcome, the Psoriatic Arthritis Impact of Disease (PsAID).
In fact, FM is associated to the final PsAID score in PsA
patients further underscoring its impact on SpA patient reported
outcomes (PROs) (49).
When focusing on the involvement of enthesis, the enthesitis
score used in SpA has been criticized owing to its lack of
correlation with objective measures of enthesitis and overlaps
with the FM tender point score (38, 62). In this regard, the Leeds
enthesitis index (LEI) is significantly higher in PsA patients with
concomitant FM.
Having concurrent FM is associated with a higher likelihood
of having received biologic therapy in a study from the British
Society for Rheumatology Biologics Register in Ankylosing
Spondylitis (BSRBR-AS) (47). Bello et al. did not observe any
differences with regard to the initiation of biologic treatment,
but reported a shorter retention rate of the first biologic after 2
years in patients with SpA and FM compared to those with SpA
only (43).
FM diagnosis could predict a lower probability to achieve
minimal disease activity or remission in patients with PsA (42,
45) and for instance the LEI is the only variable not showing a
significant reduction over time in patients treated with biologic
agents (42, 45). Finally, comorbid FM has a negative impact on
response to biologic therapies in axSpA (53). This does not reflect
a real reduced efficacy due to concomitant FM but rather the
objective and hard to overcome difficulty of patients to detach
FM and SpA symptoms when reporting their assessment of
disease activity through PROs. All these observations further
support the importance of imaging techniques as companion in
the diagnostic process to rule out FM in SpA patients and to
outline of treatment strategies in order to avoid overestimation
of SpA disease activity and therefore overtreatment.
CONCLUDING REMARKS
FM occurs in a significant proportion of SpA patients increasing
the chronic symptom burden, reducing overall function, and
worsening QoL. This has a dramatic impact not only on the
individual but more in general on society in terms of decreased
work productivity. While FM may coexist with SpA, disease
activity measures that include subjective elements, such as pain
and patient global reports may be overstated, even when more
objective measures, such as swollen joint count or CRP suggest
the achievement of remission or low disease activity. Therefore,
PROs may be less valid and reliable as a true measure of
inflammatory disease activity and to be used as a basis for
therapeutic decision-making in clinical practice in some patients
with long-standing disease, since they may lead to intensification
of, or switching immunotherapy when it is not necessarily
warranted.
On this basis, the coexistence of FM should be assessed in
patients with SpA based on the clinician’s judgment and the
use of validated positive criteria/questionnaires, instead of by
elimination criteria, with input from both patient and clinician.
In addition, sensitive and advanced imaging techniques should
be necessarily implemented to differentiate SpA inflammatory
pain from FM pain, therefore establishing the most appropriate
treatment approach in partnership with the patient.
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